Pain questionnaire performance in advanced prostate cancer: Comparative results from two international clinical trials

Quality of Life Research

Volumn 22, Issue 10, 2013, Pages 2777-2786

  Robinson Jr , Donald W ^a   Zhao, Ning ^a   Dawkins, Fitzroy ^b   Qi, Ming ^b   Revicki, Dennis ^c  

^a Janssen Global Services LLC   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Epidemiology; Pain; Prostate cancer; Psychometrics; Quality of life; Symptoms

Indexed keywords

AGED; ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; EQUIPMENT; HEALTH STATUS; HUMAN; MALE; METHODOLOGY; PAIN; PAIN ASSESSMENT; PROSTATE TUMOR; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; STATISTICS;

AGED; CLINICAL TRIALS AS TOPIC; HEALTH STATUS; HUMANS; MALE; PAIN; PAIN MEASUREMENT; PROSTATIC NEOPLASMS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 84892782249     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-013-0411-z     Document Type: Article

References (50)

1. Lee, D. J., Cha, E. K., Dubin, J. M., Beltran, H., Chromecki, T. F., Fajkovic, H., et al. (2012). Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU International, 109(7), 968-985.
2. de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet, 376(9747), 1147-1154.
3. de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364(21), 1995-2005.
4. Parker, C., Heinrich, D., O'Sullivan, J. M., Fossá, S. D., Chodacki, A., Demkow, T., et al. (2011). Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): A phase III randomized trial (ALSYMPCA). [abstract 1LBA]. European Journal of Cancer, 47(suppl 2),3
5. Mukherji, D., Pezaro, C. J., & De-Bono, J. S. (2012). MDV3100 for the treatment of prostate cancer. Expert Opinion on Investigational Drugs, 21(2), 227-233.
6. Fizazi, K., De Bono, J. S., Flechon, A., Heidenreich, A., Voog, E., Davis, N. B., et al. (2012). Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/ prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer, 48(1), 85-93.
7. Chu, F. M., Picus, J., Fracasso, P. M., Dreicer, R., Lang, Z., & Foster, B. (2011). A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human av integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Investigational New Drugs, 29(4), 674-679.
8. Atkinson, T. M., Mendoza, T. R., Sit, L., Passik, S., Scher, H. I., Cleeland, C., et al. (2010). The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: Clinical trial endpoint considerations. Pain Medicine, 11(3), 337-346.
9. Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50(6), 920-928.
10. Jensen, M. P. (2003). The validity and reliability of pain measures in adults with cancer. Journal of Pain, 4(1), 2-21.
11. Melzack, R. (1975). The McGill Pain Questionnaire: Major properties and scoring methods. Pain, 1(3), 277-299.
12. Rosenfeld, B., Roth, A. J., Gandhi, S., & Penson, D. (2004). Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psycho-oncology, 13(11), 800-807.
13. Melzack, R., & Katz, J. (2001). The McGill Pain Questionnaire: Appraisal and current status. In D. C. Turk & R. Melzack (Eds.), Handbook of pain assessment (2nd ed., pp. 35-52). New York: Guilford Press.
14. Cella, D., Nichol, M. B., Eton, D., Nelson, J. B., & Mulani, P. (2009). Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy-prostate: Results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value in Health, 12(1), 124-129.
15. Webster, K., Cella, D., & Yost, K. (2003). The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties, applications, and interpretation. Health and Quality of Life Outcomes, 1,79.
16. Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351(15), 1502-1512.
17. Halabi, S., Vogelzang, N. J., Kornblith, A. B., Ou, S.-S., Kantoff, P. W., Dawson, N. A., et al. (2008). Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. Journal of Clinical Oncology, 26(15), 2544-2549.
18. Jensen, M. P. (2008). Pain assessment in clinical trials. In H. M. Wittink & D. B. Carr (Eds.), Pain management: Evidence, outcomes, and quality of life: A sourcebook (pp. 57-88). Philadelphia: Elsevier.
19. Ferreira-Valente, M. A., Pais-Ribeiro, J. L., & Jensen, M. P. (2011). Validity of four pain intensity rating scales. Pain, 152(10), 2399-2404.
20. Cleeland, C. S., O'Mara, A., Zagari, M., & Baas, C. (2011). Integrating pain metrics into oncology clinical trials. Clinical Cancer Research, 17(21), 6646-6650.
21. Basch, E. M., Sit, L., Fruscione, M., Burke, L., Kane, R., George, D., et al. (2009). Pain and analgesic use in men with metastatic prostate cancer [abstract]. Journal of Clinical Oncology, 27(Suppl, 15S), e20515.
22. Sandblom, G., Carlsson, P., Sigsjö, P., & Varenhorst, E. (2001). Pain and health-related quality of life in a geographically defined population of men with prostate cancer. British Journal of Cancer, 85(4), 497-503.
23. Sullivan, P. W., Mulani, P. M., Fishman, M., & Sleep, D. (2007). Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Quality of Life Research, 16(4), 571-575.
24. Berthold, D. R., Pond, G. R., Roessner, M., de Wit, R., Eisenberger, M., & Tannock, A. I. (2008). Treatment of hormonerefractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clinical Cancer Research, 14(9), 2763-2767.
25. Collette, L., van Andel, G., Bottomley, A., Oosterhof, G. O., Albrecht, W., de Reijke, T. M., et al. (2004). Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. Journal of Clinical Oncology, 22(19), 3877-3885.
26. Sullivan, P. W., Nelson, J. B., Mulani, P. M., & Sleep, D. (2006). Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Quality of Life Research, 15(8), 1297-1306.
27. Armstrong, A. J., Garrett-Mayer, E., Ou Yang, Y.-C., Carducci, M. A., Tannock, I., de Wit, R., et al. (2007). Prostate-specific antigen and pain surrogacy analysis in metastatic hormonerefractory prostate cancer. Journal of Clinical Oncology, 25(25), 3965-3970.
28. Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., et al. (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 26(7), 1148-1159.
29. Armstrong, A. J., Garrett-Mayer, E. S., Yang, Y.-C., de Wit, R., Tannock, I. F., & Eisenberger, M. (2007). A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clinical Cancer Research, 13(21), 6396-6403.
30. Fayers, P. M., Hopwood, P., Harvey, A., Girling, D. J., Machin, D., & Stephens, R. (1997). Quality of life assessment in clinical trials-guidelines and a checklist for protocol writers: The U.K. Medical Research Council experience. MRC Cancer Trials Office. European Journal of Cancer, 33(1), 20-28.
31. Hahn, E. A., Webster, K. A., Cella, D., & Fairclough, D. L. (1998). Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: Problems and solutions. Statistics in Medicine, 17(5-7), 547-559.
32. Hopwood, P., Harvey, A., Davies, J., Stephens, R. J., Girling, D. J., Gibson, D., et al. (1998). Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee. European Journal of Cancer, 34(1), 49-57.
33. Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in assessing rater reliability. Psychological Bulletin, 86(2), 420-428.
34. Deyo, R. A., Diehr, P., & Patrick, D. L. (1991). Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clinical Trials, 12(4 Suppl), 142S-158S.
35. Hays, R. D., & Revicki, D. A. (2005). Reliability and validity, including responsiveness. In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials: Methods and practice (2nd ed., pp. 25-39). Oxford: Oxford University Press.
36. Yuen, K. K., Shelley, M., Sze, W. M., Wilt, T. J., & Mason, M. (2006). Bisphosphonates for advanced prostate cancer. Cochrane Database of Systematic Reviews (4), CD006250.
37. Wong, R. & Wiffen, P. J. (2002). Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Systematic Reviews (2), CD002068.
38. Mercadante, S., & Fulfaro, F. (2005). World Health Organization guidelines for cancer pain: A reappraisal. Annals of Oncology, 16(Suppl 4), iv132-iv135.
39. Bader, P., Echtle, D., Fonteyne, V., Livadas, K., De Meerleer, G., Paez Borda, A., et al. (2012). Prostate cancer pain management: EAU guidelines on pain management. World Journal of Urology, 30(5), 677-686.
40. Turk, D. C., Dworkin, R. H., Allen, R. R., Bellamy, N., Brandenburg, N., Carr, D. B., et al. (2003). Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain, 106(3), 337-345.
41. Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., et al. (2008). Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain, 9(2), 105-121.
42. Schulz, K. F., & Grimes, D. A. (2005). Multiplicity in randomised trials I: Endpoints and treatments. Lancet, 365(9470), 1591-1595.
43. Turk, D. C., Dworkin, R. H., McDermott, M. P., Bellamy, N., Burke, L. B., Chandler, J. M., et al. (2008). Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on methods, measurement, and pain assessment in clinical trials. Pain, 139(3), 485-493.
44. Ahles, T. A., Herndon, J. E, 2nd, Small, E. J., Vogelzang, N. J., Kornblith, A. B., Ratain, M. J., et al. (2004). Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: Results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer, 101(10), 2202-2208.
45. Berry, D. L., Moinpour, C. M., Jiang, C. S., Ankerst, D. P., Petrylak, D. P., Vinson, L. V., et al. (2006). Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. Journal of Clinical Oncology, 24(18), 2828-2835.
46. Oh, W. K., Manola, J., Babcic, V., Harnam, N., & Kantoff, P. W. (2006). Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology, 67(6), 1235-1240.
47. Wu, E. Q., Mulani, P., Farrell, M. H., & Sleep, D. (2007). Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value in Health, 10(5), 408-414.
48. Weinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., Glendenning, G. A., et al. (2005). The significance of skeletalrelated events for the health-related quality of life of patients with metastatic prostate cancer. Annals of Oncology, 16(4), 579-584.
49. Gater, A., Abetz-Webb, L., Battersby, C., Parasuraman, B., McIntosh, S., Nathan, F., et al. (2011). Pain in castration-resistant prostate cancer with bone metastases: A qualitative study. Health and Quality of Life Outcomes, 9(88).
50. Farrar, J. T. (2010). Advances in clinical research methodology for pain clinical trials. Nature Medicine, 16(11), 1284-1293.